Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

MedXY Editorial Team•Jan 9, 2026•Clinical Updates

The ALBAN trial (GETUG-AFU 37) is a pivotal phase III study investigating the synergy between systemic PD-L1 inhibition and local intravesical BCG in treatment-naive high-risk NMIBC.
The addition of intravenous atezolizumab to a 1-year BCG regimen failed to improve investigator-assessed event-free survival (EFS) compared to BCG monotherapy (HR 0.98).
Safety data revealed a higher incidence of treatment-related adverse events (TRAEs) in the combination arm, consistent with the known systemic profiles of checkpoint inhibitors.
Discrepancies between ALBAN and other PD-(L)1/BCG combination trials suggest that therapeutic success in NMIBC may be sensitive to specific agent characteristics and trial design.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The ALBAN trial (GETUG-AFU 37) is a pivotal phase III study investigating the synergy between systemic PD-L1 inhibition and local intravesical BCG in treatment-naive high-risk NMIBC.
The addition of intravenous atezolizumab to a 1-year BCG regimen failed to improve investigator-assessed event-free survival (EFS) compared to BCG monotherapy (HR 0.98).
Safety data revealed a higher incidence of treatment-related adverse events (TRAEs) in the combination arm, consistent with the known systemic profiles of checkpoint inhibitors.
Discrepancies between ALBAN and other PD-(L)1/BCG combination trials suggest that therapeutic success in NMIBC may be sensitive to specific agent characteristics and trial design.